NASDAQ:CLLS Cellectis Q3 2026 Earnings Date & Estimates $0.98 +0.01 (+0.67%) Closing price 10/22/2026 04:00 PM EasternExtended Trading$0.95 -0.02 (-2.46%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cellectis is estimated to report Q3 2026 earnings on Friday, November 13, 2026, after market closes. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 13, 2026TimeAfter Market Closes Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Cellectis in Q3 2026Cellectis is expected to post earnings of -$0.18 per share on revenue of $15.61 million. In the same quarter a year earlier Cellectis reported $0.01 per share on revenue of $37.16 million. Cellectis last reported on August 7, 2026, posting -$0.22 per share and beating the -$0.2630 consensus estimate. Cellectis has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.18Expected Revenue$15.61 millionPrior-Year EPS$0.01Prior-Year Revenue$37.16 millionExpected EPS Growth-1,900.0%Expected Revenue Growth-58.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.22 (Beat by +$0.0430)Last Quarter Revenue$6.90 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Cellectis Q3 2026 Earnings FAQ When does Cellectis report Q3 2026 earnings? Cellectis (NASDAQ:CLLS) is estimated to report Q3 2026 earnings on Friday, November 13, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Cellectis' Q3 2026 earnings call? Cellectis' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 3:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Cellectis? Analysts expect Cellectis to post earnings of -$0.18 per share for Q3 2026. How much revenue is Cellectis expected to report? The consensus revenue estimate for Cellectis is $15.61 million for Q3 2026. Cellectis Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLSOctober 22 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLSOctober 20 at 4:16 PM | globenewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmOctober 15, 2026 | globenewswire.comCellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G.October 15, 2026 | globenewswire.comSecurities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.October 14, 2026 | globenewswire.comSee More Cellectis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectis and other key companies, straight to your email. Email Address About CellectisCellectis (NASDAQ:CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic cell therapies for the treatment of cancer. The company uses its TALEN gene-editing technology to modify immune cells, including T cells, with the goal of creating “off-the-shelf” therapies that can be manufactured in advance and administered to multiple patients. Cellectis’ development programs include UCART, or Universal Chimeric Antigen Receptor T-cell, therapies designed to target specific cancer antigens. Its research and development activities cover hematologic malignancies and solid tumors, with programs involving engineered T cells and other genetically modified immune-cell products. The company’s approach is intended to improve the scalability and accessibility of cell therapy compared with treatments manufactured individually for each patient. Founded in France in 1999, Cellectis has operations and research activities in Europe and the United States and conducts clinical development internationally. The company was co-founded by André Choulika and David Sourdive; David Sourdive has served as chief executive officer. Cellectis has also pursued strategic collaborations to advance the development and potential commercialization of its gene-edited cell therapies.View Cellectis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Texas Paused Data Center Hookups—2 Power Stocks Are Waiting on the VerdictIs Texas Instruments Setting Up for Its Next Big Breakout?Lam Research's Earnings Beat Wasn't the Real Story—Its 2027 Outlook WasTesla’s Flying-Car Hype Hits an Earnings Reality CheckMeta Bounces Back in Q3, But the Bigger Test Comes in 2027Cologuard Is Working—So Why Isn’t Abbott Stock?Pegasystems' Q3 Miss Exposed the Problem Standing Between AI and Cash Flow Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
